Working Paper Review Version 1 This version is not peer-reviewed

Immunogenicity of Clinically Relevant SARS-CoV-2 Vaccines in Non-human Primates and Humans

Version 1 : Received: 2 September 2020 / Approved: 7 September 2020 / Online: 7 September 2020 (12:29:06 CEST)

How to cite: Klasse, P.; Nixon, D.F.; Moore, J.P. Immunogenicity of Clinically Relevant SARS-CoV-2 Vaccines in Non-human Primates and Humans. Preprints 2020, 2020090166 Klasse, P.; Nixon, D.F.; Moore, J.P. Immunogenicity of Clinically Relevant SARS-CoV-2 Vaccines in Non-human Primates and Humans. Preprints 2020, 2020090166

Abstract

Multiple preventive vaccines are being developed to counter the COVID-19 pandemic. The leading candidates have now been evaluated in non-human primates (NHPs) and human Phase 1 and/or Phase 2 clinical trials. Several vaccines have already advanced into Phase 3 efficacy trials, while others will do so before the end of 2020. Here, we summarize what is known of the antibody and T-cell immunogenicity of these vaccines in NHPs and humans. To the extent possible, we compare how the vaccines have performed, taking into account the use of different assays to assess immunogenicity and inconsistencies in how the resulting data are presented. We also summarize the outcome of SARS-CoV-2 challenge experiments in immunized macaques, while noting variations in the protocols used, including but not limited to the virus challenge doses.

Subject Areas

SARS-CoV-2; S-protein; RBD; COVID-19; neutralizing antibodies; serology; T-cells; vaccines; animal models; Operation Warp Speed

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.